AMRX FY 2018 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

FY 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.7B+60.9% YoY

Gross Profit

$716M43.1% margin

Operating Income

-$20M-1.2% margin

Net Income

-$170M-10.2% margin

EPS (Diluted)

$-1.33

Cash Flow

Operating Cash Flow

$250M

Free Cash Flow

$153M

Stock-Based Comp.

$168M

Balance Sheet

Total Assets

$4.4B

Total Liabilities

$3.5B

Stockholders' Equity

$896M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.7B	$1.0B	+60.9%
Gross Profit	$716M	$526M	+36.2%
Operating Income	-$20M	$245M	-108.0%
Net Income	-$170M	$168M	-201.2%